ASTELLAS PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,528 JPY | -0.88% |
|
-1.96% | -9.40% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 | 1,604B 10.29B | Sales 2025 * | 1,656B 10.63B | Capitalization | 2,739B 17.58B |
|---|---|---|---|---|---|
| Net income 2024 | 17.04B 109M | Net income 2025 * | 103B 658M | EV / Sales 2024 | 1.84 x |
| Net Debt 2024 * | 503B 3.23B | Net Debt 2025 * | 512B 3.29B | EV / Sales 2025 * | 1.96 x |
| P/E ratio 2024 |
173
x | P/E ratio 2025 * |
26.8
x | Employees | 14,484 |
| Yield 2024 |
4.26% | Yield 2025 * |
4.92% | Free-Float | 98.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Astellas Pharma Inc.
More recommendations
More press releases
More news
| 1 day | -0.88% | ||
| 1 week | -1.96% | ||
| Current month | +0.89% | ||
| 1 month | -2.95% | ||
| 3 months | -5.45% | ||
| 6 months | -14.66% | ||
| Current year | -9.40% |
1 week
1 518.00
1 573.50
1 month
1 426.001 585.00
Current year
1 426.001 801.50
1 year
1 426.002 360.50
3 years
1 426.002 360.50
5 years
1 375.002 360.50
10 years
1 175.002 360.50
| Managers | Title | Age | Since |
|---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 86-03-31 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | Oct. 31 |
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 67 | 21-05-31 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 17-05-31 |
Kenji Yasukawa
CHM | Chairman | 63 | 86-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 11.47% | 0 M€ | +11.43% | ||
| 2.09% | 0 M€ | +13.17% | ||
| 2.01% | 0 M€ | +20.78% | ||
| 1.99% | 0 M€ | +13.64% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1,528 | -0.88% | 6,638,000 |
| 24-05-09 | 1,541 | -0.23% | 5,938,700 |
| 24-05-08 | 1,544 | -1.15% | 7,330,800 |
| 24-05-07 | 1,562 | +0.29% | 7,722,200 |
Delayed Quote Japan Exchange, May 10, 2024 at 02:00 am EDT
More quotes
Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders.
Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,528
JPY
Average target price
2,009
JPY
Spread / Average Target
+31.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.40% | 17.57B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- 4503 Stock